Cargando…

1790. Dethroning Vancomycin: A Multifaceted Stewardship Approach to Reduce Vancomycin in an Academic Medical Center

BACKGROUND: Vancomycin is a broadly used antimicrobial, and from 2014-2022 represented the most used antibiotic at our academic medical center. Since 2015, the stewardship program has introduced several measures to optimize vancomycin use including pharmacy consultation, addition of MRSA nares PCR t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lusardi, Katherine, Bailey, Brett, Rico Crescencio, Juan Carlos, Awad, Ramez, Jenkins, Mitchell, Dare, Ryan K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753005/ http://dx.doi.org/10.1093/ofid/ofac492.1420

Ejemplares similares

AVDS should not dethrone ARDS
por: Mahjoub, Yazine, et al.
Publicado: (2021)

223. Impact of Different Stewardship Strategies Applied to a Single Antibiotic Over Time
por: Lusardi, Katherine, et al.
Publicado: (2018)

Dethroning Contrast Angiography: A Place for Electroanatomic Mapping?
por: Kleiman, Neal S.
Publicado: (2022)

46. Antimicrobial Stewardship’s Selective Antibiotic Suppression Does Not Lead to Adverse Outcomes in Neutropenic Patients with Gram-Negative Bacteremia
por: Witt, Anna, et al.
Publicado: (2020)

Effects of staff education and standardizing dosing and collection times on vancomycin trough appropriateness in ward patients
por: Hammond, Drayton A., et al.
Publicado: (2017)

Vancomycin-resistant enterococci: eradication using vancomycin?
por: Van Prehn, J, et al.
Publicado: (2014)

Vancomycin-Associated Tubular Casts and Vancomycin Nephrotoxicity
por: Tantranont, Ngoentra, et al.
Publicado: (2021)

160. Measuring the Impact of PCR-based MRSA Nares Screening on Vancomycin Use and Duration of Vancomycin Among Pneumonia Patients at an Academic Medical Center
por: Stromberg, Joseph, et al.
Publicado: (2023)

Dethroning the crown. From the kinetics and dynamics of COVID–19 diagnosis to promising treatments
por: Nikolouzakis, Taxiarchis Konstantinos, et al.
Publicado: (2021)

The Dethroning of 6 ml/kg as the “Go-To” Setting in Acute Respiratory Distress Syndrome
por: Tobin, Martin J.
Publicado: (2021)

Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital
por: van der Pol, Simon, et al.
Publicado: (2023)

Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
por: Shlezinger, Mor, et al.
Publicado: (2019)

229. The Role of Antimicrobial Stewardship Program on Appropriate Use, Dose, and Duration of Vancomycin Treatment
por: Kaplun, Olga, et al.
Publicado: (2018)

Impact of a monthly antimicrobial stewardship quality assurance tool for elevated vancomycin levels
por: Knack, Olivia C., et al.
Publicado: (2023)

1223. Utilizing Multiple Antimicrobial Stewardship Metrics to Trend Vancomycin Use in an Implementation Study
por: Wolfe, Kaleb H, et al.
Publicado: (2023)

Enhanced Efficacy of High Dose Oral Vancomycin Therapy in Clostridium difficile Diarrhea for Hospitalized Adults Not Responsive to Conventional Oral Vancomycin Therapy: Antibiotic Stewardship Implications
por: Cunha, Burke A., et al.
Publicado: (2018)

The Nephrotoxicity of Vancomycin
por: Filippone, EJ, et al.
Publicado: (2017)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

1076. Antimicrobial Stewardship Program Achieves Marked Decrease in the use of Vancomycin in a Veterans Hospital
por: Ford, Florence M, et al.
Publicado: (2019)

Implementation of a hospital antimicrobial stewardship program to improve vancomycin use in Cyprus: Challenges and opportunity
por: Papastergiou, Panagiotis, et al.
Publicado: (2022)

Molecular Characterization of Virulence Genes in Vancomycin-Resistant and Vancomycin-Sensitive Enterococci
por: Biswas, Priyanka Paul, et al.
Publicado: (2016)

Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates
por: Samardzic, Janko, et al.
Publicado: (2016)

Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
por: Hu, Qiwen, et al.
Publicado: (2016)

Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci
por: Mühlberg, Eric, et al.
Publicado: (2020)

Vancomycin nephrotoxicity: Vancomycin tubular casts with characteristic electron microscopic findings
por: Tantranont, Ngoentra, et al.
Publicado: (2019)

Virulence factors in vancomycin-resistant and vancomycin- susceptible Enterococcus faecalis from Brazil
por: Camargo, I. L. B. C., et al.
Publicado: (2008)

In vitro efficacy of vancomycin combined with fosfomycin against Vancomycin-Resistant Enterococci strains
por: Aktas, Gulseren
Publicado: (2020)

1955. Novel Compound Reverses Vancomycin Resistance in Vancomycin-resistant Enterococci (VRE)
por: Onyedibe, Kenneth, et al.
Publicado: (2019)

Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains
por: Aktas, Gulseren
Publicado: (2020)

Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
por: Sipahi, Oguz Resat, et al.
Publicado: (2023)

224. Cost Analysis of a Significant Decrease in Vancomycin Use as a Result of an Antimicrobial Stewardship Intervention
por: Hodgson, Hayley, et al.
Publicado: (2018)

110. MRSA nasal swab as a stewardship tool to guide IV Vancomycin in diabetic foot infections
por: Lazo-Vasquez, Alex, et al.
Publicado: (2021)

621. Identifying Quality-Improvement Interventions to Improve Inpatient Intravenous Vancomycin Safety at an Academic Medical Center
por: Christensen, Sean, et al.
Publicado: (2021)

Vancomycin Activates σ(B) in Vancomycin-Resistant Staphylococcus aureus Resulting in the Enhancement of Cytotoxicity
por: Chen, Hong-Yi, et al.
Publicado: (2011)

Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013)

Draft Genome Sequence of a Vancomycin-Resistant and Vancomycin-Dependent Enterococcus faecium Isolate
por: Blaschitz, Marion, et al.
Publicado: (2016)

Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
por: Lin, Lee-Chung, et al.
Publicado: (2018)

Peptidoglycan O-acetylation increases in response to vancomycin treatment in vancomycin-resistant Enterococcus faecalis
por: Chang, James D., et al.
Publicado: (2017)

Impact of Vancomycin Serum Trough Concentrations and Vancomycin AUC/MIC on Vancomycin Response, In-Hospital Outcomes and Acute Kidney Injury in Pediatric Staphylococcus aureus Pneumonia
por: McNeil, Jonathon, et al.
Publicado: (2017)

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
por: Shariati, Aref, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_drb206tqgueu3e7fabk6pduv9b